Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)

Background Pancreatic cancer is one of the deadliest cancer types and represents a major unmet medical need. CheckMate 032 investigated safety and efficacy of nivolumab monotherapy and nivolumab plus ipilimumab with/without cobimetinib in advanced/metastatic solid tumors, including pancreatic cancer...

Full description

Bibliographic Details
Main Authors: Padmanee Sharma, Asim Amin, Dung T Le, Michael A Morse, Marina Tschaika, Matthew H Taylor, Margaret Callahan, Katriina J Peltola, Frederic J Kaye, Eileen M O'Reilly, Stephanie Meadows Shropshire, Shaun O'Brien
Format: Article
Language:English
Published: BMJ Publishing Group 2024-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/2/e007883.full

Internet

https://jitc.bmj.com/content/12/2/e007883.full

Similar Items